The Latest Analyst Ratings for Fulcrum Therapeutics
Portfolio Pulse from Benzinga Insights
Fulcrum Therapeutics (NASDAQ:FULC) has received various analyst ratings in the last quarter, with an average price target of $10.2, a significant increase from its current price of $4.17. The average price target has increased by 104.0% over the past month.
September 25, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fulcrum Therapeutics has received positive analyst ratings, with a significant increase in the average price target over the past month.
The positive analyst ratings and the significant increase in the average price target suggest a bullish outlook for Fulcrum Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100